BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 24451719)

  • 1. Establishing the standard of care for patients with newly diagnosed and recurrent glioblastoma.
    Gilbert MR
    Am Soc Clin Oncol Educ Book; 2012; ():112-7. PubMed ID: 24451719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Insight: temozolomide as a treatment for malignant glioma--impact of a recent trial.
    Mason WP; Cairncross JG
    Nat Clin Pract Neurol; 2005 Dec; 1(2):88-95. PubMed ID: 16932504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy.
    Chamberlain MC
    Int J Clin Pract; 2013 Dec; 67(12):1225-7. PubMed ID: 24246204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
    Schiff D; Desjardins A; Cloughesy T; Mikkelsen T; Glantz M; Chamberlain MC; Reardon DA; Wen PY
    Cancer; 2016 Feb; 122(4):582-7. PubMed ID: 26588662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
    Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
    J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of dose-escalating metronomic temozolomide plus bevacizumab and bortezomib for patients with recurrent glioblastoma.
    McCracken DJ; Celano EC; Voloschin AD; Read WL; Olson JJ
    J Neurooncol; 2016 Oct; 130(1):193-201. PubMed ID: 27502784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment options for glioblastoma.
    Chamberlain MC
    Neurosurg Focus; 2006 Apr; 20(4):E19. PubMed ID: 16709025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
    Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
    J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of the EORTC/NCIC Trial Protocol in a Neurosurgical Outpatient Unit: The Case for Neurosurgical Neuro-Oncology.
    Rapp M; Sadat H; Slotty PJ; Steiger HJ; Budach W; Sabel M
    J Neurol Surg A Cent Eur Neurosurg; 2015 Jul; 76(4):298-302. PubMed ID: 25915500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dense temozolomide: is it still promising?
    Nagane M
    Neurol Med Chir (Tokyo); 2015; 55(1):38-49. PubMed ID: 25744349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival improvements with adjuvant therapy in patients with glioblastoma.
    Jayamanne D; Wheeler H; Cook R; Teo C; Brazier D; Schembri G; Kastelan M; Guo L; Back MF
    ANZ J Surg; 2018 Mar; 88(3):196-201. PubMed ID: 28922698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of glioblastoma.
    Aoki T; Hashimoto N; Matsutani M
    Expert Opin Pharmacother; 2007 Dec; 8(18):3133-46. PubMed ID: 18035958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
    Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
    Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
    Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
    J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
    Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
    van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
    Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.